Key result
Newer anticoagulants such as ximelagatran were associated with increased rates of serious arterial adverse events compared to warfarin or placebo (0.75% vs 0.26%; p<0.05).
Why the study?
Does the cessation of newer anticoagulant drugs cause a rebound effect (increased thromboembolic events) compared to standard anticoagulant therapy?
Population
Patients receiving anticoagulant treatments for primary prevention of venous thromboembolism in major…
Comparison
Newer anticoagulant drugs vs Standard anticoagulant therapy
Design
Systematic_review
Authors
Loading...
Alerts clinicians to arterial risks with ximelagatran; confirms rebound concerns in systematic evidence.
Does the cessation of newer anticoagulant drugs cause a rebound effect (increased thromboembolic events) compared to standard anticoagulant therapy?
Absolute Event Rate: 0.75% vs 0.26%
p-value: p=<0.05
There is limited but concerning evidence suggesting a potential rebound increase in thromboembolic events following the cessation of newer anticoagulants like ximelagatran compared to standard therapy.
Hermans et al. (2006) conducted a review in Venous thromboembolism and atrial fibrillation. Newer anticoagulants (e.g., ximelagatran, fondaparinux) vs. Standard anticoagulant therapy (warfarin/placebo) was evaluated on Serious arterial adverse events (short-term exposure) (p=<0.05). Newer anticoagulants such as ximelagatran were associated with increased rates of serious arterial adverse events compared to warfarin or placebo (0.75% vs 0.26%; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: